Skip to main content
Clinical Trials/NCT06205199
NCT06205199
Completed
Not Applicable

Analgesic Effect of Ropivacaine Hydrochloride Combined With Hydromorphone Hydrochloride for Combined Spinal-epidural Anesthesia After Total Knee Arthroplasty

Second Hospital of Jilin University1 site in 1 country136 target enrollmentOctober 27, 2022

Overview

Phase
Not Applicable
Intervention
Hydromorphone was injected into the subarachnoid space
Conditions
Postoperative Analgesia
Sponsor
Second Hospital of Jilin University
Enrollment
136
Locations
1
Primary Endpoint
Incidence of moderate to severe pain at rest at 6, 12, 18, and 24 hours after anesthesia.
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

The aim of this study is to investigate the continuous analgesic effect and side effects of ropivacaine combined with hydromorphone for combined spinal-epidural anesthesia(CSEA) after total knee arthroplasty and to explore its clinical application value. To observe whether hydromorphone combined with ropivacaine can promote the rapid recovery of patients.

Detailed Description

For patients undergoing total knee arthroplasty, different spinal anesthesia drugs were injected in the two groups. The spinal anesthetic drugs injected in the hydromorphone group were hydromorphone 50 μg and ropivacaine 15 mg. In the control group, the spinal anesthetic was ropivacaine 15 mg.The differences in analgesia, sedation, and side effects between the hydromorphone group and the control group were analyzed by collecting various data at different times after anesthesia.

Registry
clinicaltrials.gov
Start Date
October 27, 2022
End Date
November 30, 2023
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Second Hospital of Jilin University
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age between 55 and 80 years old.
  • ASA grade I to III.
  • BMI:20-29kg/m
  • No recent use of sedatives, opioids, or other analgesics.
  • There was no contraindication of spinal anesthesia, severe dysfunction of heart, lung and other important organs or serious systemic diseases.
  • Patients were willing to participate in the study and signed the informed consent.

Exclusion Criteria

  • The patient has mental illness or cannot cooperate with the completion of spinal anesthesia.
  • The patient had a history of spinal surgery and spinal deformity.
  • Patients had a history of opioid intolerance or adverse reactions.
  • puncture site infection, coagulopathy or recent use of anticoagulant drugs.
  • History of allergy to local anesthetics.
  • Failed puncture.
  • Unable to cooperate to complete the research process.

Arms & Interventions

Hydromorphone group

Hydromorphone 50 micrograms combined with ropivacaine 15 mg was injected into the subarachnoid space

Intervention: Hydromorphone was injected into the subarachnoid space

Outcomes

Primary Outcomes

Incidence of moderate to severe pain at rest at 6, 12, 18, and 24 hours after anesthesia.

Time Frame: 6, 12, 18, and 24 hours after anesthesia

The NRS scale was used to evaluate pain scores at rest at 6, 12, 18, and 24 hours after anesthesia;Numeric rating scale (NRS, an 11-point scale where 0=no pain and 10=worst possible pain)

Incidence of moderate to severe pain with movement at 6, 12, 18, and 24 hours after anesthesia.

Time Frame: 6, 12, 18, and 24 hours after anesthesia

NRS rating scale was used to evaluate pain score during movement at 6 hours, 12 hours, 18 hours, and 24 hours after anesthesia;Numeric rating scale (NRS, an 11-point scale where 0=no pain and 10=worst possible pain)

Secondary Outcomes

  • Sedation and agitation at 6, 12, 18 and 24 hours after anesthesia(6, 12, 18, and 24 hours after anesthesia)
  • Total non-steroidal analgesic drug consumption 48 hours after surgery(Postoperative 48 hours)
  • Length of postoperative hospital stay(2 weeks after surgery)
  • The incidence of postoperative nausea or vomiting(Postoperative 48 hours)
  • The incidence of intraoperative hypoxemia(During the operation)
  • Incidence of intraoperative HR reduction(During the operation)
  • Satisfaction with postoperative analgesia(5 days after surgery)
  • Retention time of urinary tube(5 days after surgery)
  • The number of effective compressions of PCIA at 24 hours after surgery(Postoperative 24 hours)
  • The proportion of the required additional analgesia after 24 hours(Postoperative 24 hours)
  • Total opioid analgesic consumption at 48 hours after surgery(Postoperative 48 hours)
  • The proportion of getting out of bed within 48h(Postoperative 48 hours)
  • The incidence of postoperative pruritus(Postoperative 48 hours)
  • The incidence of intraoperative hypotension(During the operation)

Study Sites (1)

Loading locations...

Similar Trials